

Carlos Lopez Lopez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6655092/publications.pdf>

Version: 2024-02-01

56
papers

4,767
citations

394421

19
h-index

206112

48
g-index

57
all docs

57
docs citations

57
times ranked

6402
citing authors

#	ARTICLE	IF	CITATIONS
1	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. <i>Neuroendocrinology</i> , 2022, 112, 88-100.	2.5	6
2	Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4078-4078.	1.6	0
3	Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. <i>European Thyroid Journal</i> , 2022, 11, .	2.4	2
4	Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability. <i>Neuroendocrinology</i> , 2021, 111, 831-839.	2.5	7
5	Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. <i>Pancreatology</i> , 2021, 21, 215-223.	1.1	2
6	Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4113-4113.	1.6	2
7	Sunitinib and Evofosfamide (<sc>TH</sc>-302) in Systemic Treatment-Na ⁺ Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <sc>GETNE</sc>-1408 Trial. <i>Oncologist</i> , 2021, 26, 941-949.	3.7	12
8	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	1.6	49
9	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	8.1	58
10	Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , 2020, 26, 902-909.	7.0	29
11	VITAL phase 2 study: Upfront 5-Fluorouracil, mitomycin, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09). <i>Cancer Medicine</i> , 2020, 9, 1008-1016.	2.8	12
12	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 93-104.	7.7	60
13	Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. <i>BMC Cancer</i> , 2020, 20, 1164.	2.6	7
14	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. <i>PLoS ONE</i> , 2020, 15, e0235848.	2.5	14
15	Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. <i>International Journal of Colorectal Disease</i> , 2020, 35, 739-746.	2.2	12
16	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1754-1759.	6.4	17
17	GETNE-SILVELLUL study: A new immunohistochemical score (SPI) in patients (pts) with pancreatic neuroendocrine tumors (PanNET) treated with everolimus or captem.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16707-e16707.	1.6	0
18	Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 520-520.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
20	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
21	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
22	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
23	Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. <i>Oncologist</i> , 2019, 24, 38-46.	3.7	23
24	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2571-2580.	1.6	49
25	Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study. <i>Clinical Cancer Research</i> , 2019, 25, 6692-6699.	7.0	18
26	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 378-383.	6.4	2
27	Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1566.	7.1	36
28	Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). <i>British Journal of Cancer</i> , 2019, 121, 537-544.	6.4	18
29	Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. <i>Oncologist</i> , 2019, 24, e687-e695.	3.7	19
30	Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881982821.	3.2	8
31	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	8.1	36
32	Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET) – The GREPONET Study. <i>Oncologist</i> , 2019, 24, e1082-e1090.	3.7	26
33	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. <i>Cells</i> , 2019, 8, 1506.	4.1	18
34	The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of the combination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4105-4105.	1.6	5
35	Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4109-4109.	1.6	4
36	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 186-186.	1.6	35

#	ARTICLE	IF	CITATIONS
37	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	10.7	285
38	Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). <i>Oncologist</i> , 2018, 23, 422-432.	3.7	66
39	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2018, 391, 1163-1173.	13.7	3,542
40	Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis. <i>Journal of Geriatric Oncology</i> , 2018, 9, 254-264.	1.0	14
41	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. <i>Targeted Oncology</i> , 2018, 13, 69-78.	3.6	0
42	Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. <i>BMC Cancer</i> , 2018, 18, 1185.	2.6	26
43	Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2017, 19, 72.	4.0	13
44	Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. <i>British Journal of Cancer</i> , 2017, 117, 775-782.	6.4	77
45	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. <i>Future Oncology</i> , 2017, 13, 615-624.	2.4	32
46	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 465-474.	5.3	20
47	A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the) Tj ETQq1 1 0.784314 3gBT /Over		
48	Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. <i>BMC Cancer</i> , 2016, 16, 858.	2.6	6
49	Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, e17553-e17553.	1.6	1
50	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. <i>BMC Cancer</i> , 2015, 15, 60.	2.6	41
51	Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. <i>BMC Cancer</i> , 2015, 15, 495.	2.6	25
52	Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profileâ€”VITAL study, GEMCAD 09-02 clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4034-4034.	1.6	2
53	Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs.. <i>Journal of Clinical Oncology</i> , 2014, 32, 484-484.	1.6	1
54	NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinomaâ€”R0 resection, pCR, and toxicity analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4098-4098.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Current situation of zalutumumab. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 667-674.	3.1	15
56	Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer. <i>Acta Oncológica</i> , 2008, 47, 1584-1589.	1.8	0